收藏切换
Research progress in almonertinib in the treatment of advanced non-small cell lung cancer
收藏切换
Yuhao FU1, 2, Xuejiao XUN1, 2, Xueru HE1, 2, Ran FU1, 2, Yanjun CUI1, 2, Zhanjun DONG2, *
World Clinical Drug | 2022, 43(3) : 325 - 330
Less
收藏切换
World Clinical Drug | 2022, 43(3): 325-330
• Review •
Research progress in almonertinib in the treatment of advanced non-small cell lung cancer
Full
Yuhao FU1, 2, Xuejiao XUN1, 2, Xueru HE1, 2, Ran FU1, 2, Yanjun CUI1, 2, Zhanjun DONG2, *
Affiliations
  • 1.Graduate School of Hebei Medical University, Shijiazhuang 050017, Hebei Province, China
  • 2.Department of Pharmacy, Hebei General Hospital, Shijiazhuang 050051, Hebei Province, China
Published: 2022-03-10 doi: 10.13683/j.wph.2022.03.020
Outline
收藏切换

Lung cancer is one of the most common malignant tumors in the world, and it is also the leading cause of cancer-related death. Non-small cell lung cancer (NSCLC) is the main type of lung cancer, and epidermal growth factor receptor (EGFR) gene mutation is a common driving gene for NSCLC. The first and second generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective in the treatment of NSCLC with EGFR mutation-positive, but they are prone to drug resistance caused by T790M mutation. Almonertinib is a noval and irreversible third generation EGFR-TKI independently developed in China. It has high selectivity to EGFR sensitization and T790M drug resistance mutation and also has good central nervous system activity and tolerance. In this paper, we reviewed the mechanism of action, pharmacodynamics, pharmacokinetics, clinical research and combination therapy of almonertinib, to provide a reference for clinical application.

almonertinib  /  non-small cell lung cancer  /  epidermal growth factor receptor tyrosine kinase inhibitor
付裕豪, 荀雪姣, 何雪茹, 付冉, 崔艳军, 董占军. 阿美替尼治疗晚期非小细胞肺癌的研究进展. 世界临床药物, 2022 , 43 (3) : 325 -330 . DOI: 10.13683/j.wph.2022.03.020
Yuhao FU, Xuejiao XUN, Xueru HE, Ran FU, Yanjun CUI, Zhanjun DONG. Research progress in almonertinib in the treatment of advanced non-small cell lung cancer[J]. World Clinical Drug, 2022 , 43 (3) : 325 -330 . DOI: 10.13683/j.wph.2022.03.020
Year 2022 volume 43 Issue 3
14
3
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2022.03.020
  • Receive Date:2021-08-26
  • Online Date:2026-11-19
  • Published:2022-03-10
Article Data
Affiliations
History
  • Received:2021-08-26
Funding
Affiliations
    1.Graduate School of Hebei Medical University, Shijiazhuang 050017, Hebei Province, China
    2.Department of Pharmacy, Hebei General Hospital, Shijiazhuang 050051, Hebei Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.03.020
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT